Nektar Therapeutics (NKTR) Stock
NASDAQ · NKTR
67.10
Fundamentals
Market cap
$2.29B
Price / Earnings ratio
-14.9x
Price / Sales ratio
42.8x
Price / Book ratio
2.6x
Return on assets
-0.4%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
SectorHealthcare
IndustryBiotechnology
Employees63
CEOMr. Howard W. Robin
IPO DateMay 3, 1994
HeadquartersSan Francisco, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Howard W. Robin | CEO, President & Director | 1953 |
| Dr. Jonathan Zalevsky Ph.D. | Senior VP and Chief Research & Development Officer | 1975 |
| Ms. Linda M. Rubinstein M.A. | CFO and Principal Financial & Accounting Officer | 1967 |
| Mr. Jason Barnard | Chief Accounting Officer | — |
| Ms. Elizabeth Zhang | VP of Legal, Corporate Counsel & Secretary | — |
| Mr. Robert Bacci | Chief People Officer and Head of Quality & Facilities | — |
| Ms. Jennifer Ruddock | Chief Business Officer | — |
| Dr. Mary Tagliaferri L.Ac., M.D. | Chief Medical Officer | 1966 |
| Dr. Ken Franke Ph.D. | Senior Vice President of Biologics Process Development & Manufacturing | — |
| Ms. Charleen Jue | Senior Vice President of Clinical Development Operations | — |
Fundamentals
Valuation
Market cap$2.29B
Price-to-sales ratio42.76
Price-to-book value2.58
Price-earnings ratio-14.90
Return on Equity-87.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratio0.31
Earnings Per Share
Earnings Per Share$-6.51
Income Statement
Average volume691,810
EBITDA$-128.32M
1 year high (52w)$109.00
1 year low (52w)$33.40
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



